A solution for early HCC detection? Exactly.

The Oncoguard® Liver solution is helping us make early-stage detection of hepatocellular carcinoma (HCC) a reality for more patients.

Liver cancer is the fastest growing cause of cancer-related death in the United States.

Beyond 2035, it is expected to surpass colorectal and breast cancer to be the third leading cause of cancer-related death.1


Outcomes for hepatocellular carcinoma (HCC), the most common type of liver cancer, are improved with early-stage detection. However, most cases of HCC are detected in late stages when curative treatments are no longer an option.2,3

Routine surveillance to find early-stage HCC in at-risk patients is the key to giving these patients the chance they each deserve at successful, even curative treatment. However, conventional assessment for HCC is often suboptimal, and far too many patients at risk for HCC do not adhere to guideline-recommended surveillance.2,4


A meta-analysis of 32 studies found that using both ultrasound and alpha-fetoprotein (AFP) detected early-stage HCC with only 63% sensitivity, and 47% sensitivity with ultrasound alone.

Undertaking surveillance with AFP alone missed most early-stage disease.5


A meta-analysis assessing patient adherence to HCC surveillance found that surveillance utilization is estimated at 24%.4


Exactly the right solution for at-risk patients

With a comprehensive approach to HCC detection in mind, the Oncoguard® Liver solution was designed to bring better outcomes within reach for more patients at risk for HCC.


The Oncoguard® Liver solution is exactly what’s needed to bridge gaps in HCC detection


Enhanced performance to enable early-stage HCC detection versus other guideline-recommended blood tests.


Easy access to testing with a simple, smart, and convenient blood test.


Improved patient adherence to routine testing through a flexible Patient Engagement Program.

healthcare provider

For healthcare providers

The Oncoguard® Liver solution offers a powerful combination of performance, accessibility, and adherence support for a streamlined approach to HCC detection.

Learn about the science, applicability, and logistics of the Oncoguard® Liver solution.

References: 1. Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Network Open. 2021;4(4):e214708. 2. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11(4):e1001624. 3. Choi DT, Kum HC, Park S, et al. Hepatocellular carcinoma screening is associated with increased survival of patients with cirrhosis. Clin Gastroenterol Hepatol. 2019;17(5):976-987.e4. 4. Wolf E, Rich NE, Marrero JA, Parikh N, Singal AG. Utilization of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis. [published online ahead of print, 2020 May 8]. Hepatology. 2020;10.1002/hep.31309. 5. Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706-1718.e1.